75
Views
1
CrossRef citations to date
0
Altmetric
Review

Natalizumab in the treatment of Crohn’s disease

&
Pages 275-284 | Published online: 07 Dec 2022

Figures & data

Figure 1 Adhesion molecules (integrins) mediate the selective binding between the leukocytes and the endothelial cells to migrate from the vessels to the inflamed intestinal muocsa, through four phases: attachment, rolling, arrest, and transmigration. The toxic metabolites, cytokines, and chemioactractans, produced by the inflammation source, induce and drive the trafficking of immune cells to final destination.

Figure 1 Adhesion molecules (integrins) mediate the selective binding between the leukocytes and the endothelial cells to migrate from the vessels to the inflamed intestinal muocsa, through four phases: attachment, rolling, arrest, and transmigration. The toxic metabolites, cytokines, and chemioactractans, produced by the inflammation source, induce and drive the trafficking of immune cells to final destination.

Figure 2 Pharmacological targets of natalizumab. Several adhesion molecules are espressed on the surface of endothelial and immune system cells. In particluar, natalizumab inhibits the interaction between α4β1and α4β7 integrins expressed on the surface of T lymphocyte cells, and VCAM-1 and MAdCAM-1 expressed on the surface of endothelial cells.

Figure 2 Pharmacological targets of natalizumab. Several adhesion molecules are espressed on the surface of endothelial and immune system cells. In particluar, natalizumab inhibits the interaction between α4β1and α4β7 integrins expressed on the surface of T lymphocyte cells, and VCAM-1 and MAdCAM-1 expressed on the surface of endothelial cells.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.